

Receipt date: 09/09/2011

Docket No. 100-8024C/C1/D1

OK TO ENTER: /SH/

09/12/2011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Sedrani et al.

APPLICATION NO: 09/585,743

FILED: June 2, 2000

FOR: Rapamycin Assay

Art Unit: 1641

Examiner: HAQ, SHAFIQUL

Confirmation No. 7135

MS: Amendment After Notice of Allowance

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

AMENDMENT AFTER NOTICE OF ALLOWANCE 37 CFR 1.312

AND LETTER CORRECTING OFFICIAL FILING RECEIPT

Dear Sir:

By this paper, Applicants wish to amend the specification of the above referenced application as follows:

Amendments to the specification are given on page 2 of this paper; and

Remarks/Arguments begin on page 3 of this paper.

Receipt date: 09/09/2011

Application No. 09/585,743

Attorney Docket No. Case 100-8024C/C1/D1

Amendments to the specification

Please add the following new paragraph on page 1 after the title:

--This Application is a Divisional of United States Appln. 09/072,278 filed May 4, 1998 which is a Continuation of United States Appln. 08/532,837 filed October 5, 1995, which is a 371 Filing of PCT/EP94/01006 filed March 30, 1994, which claims priority of UK Application 94307491.2 filed April 8, 1993, the entire disclosures of which are claimed herein.--

Receipt date: 09/09/2011

Application No. 09/585,743

Attorney Docket No. Case 100-8024C/C1/D1

REMARKS

Applicant would like to thank Examiner Haq for discussing the present case with Applicants on September 8, 2011. Applicants discussed with Examiner Haq the best means to ensure acknowledgement of the continuing data and priority chain for the present application. Upon review of the file Applicants noticed that the filing receipt does not include the complete continuing data for the present application. Support for amendment and correction of the continuing data can be found in the Oath and Declaration and the Transmittal, which were both submitted with the filing of the present application on June 2, 2000.

Please issue a corrected filing receipt listing the "Continuing Data as Claimed by Applicant" as follows:

--This Application is a Divisional of United States Appln. 09/072,278 filed May 4, 1998 which is a Continuation of United States Appln. 08/532,837 filed October 5, 1995, which is a 371 Filing of PCT/EP94/01006 filed March 30, 1994, which claims priority of UK Application 94307491.2 filed April 8, 1993.--

A copy of the filing receipt with the correction noted is enclosed as well as a new Application Data Sheet.

Applicants believe that no fees are due with this filing. However, if any fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936

/Christine McCormack/

Christine McCormack
Attorney for Applicant
Reg. No. 61,331
(617) 871-8486

Date: September 9, 2011